Sign inJoin waitlistJoin the waitlist

Danielle Marie Brander

Associate Professor of Medicine · Duke Department of Medicine

Credentials: ·

History

Duke Department of Medicine
Present
Duke Cancer Institute
Present

Duke University School of Medicine
2007

Research

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
New England Journal of Medicine · 2018 · 782 citations
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Haematologica · 2018 · 406 citations
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
The Lancet Oncology · 2017 · 284 citations

Anthony Mato
27 papers
Mazyar Shadman
24 papers
Brian Hill
21 papers
Stephen Schuster
19 papers
Jennifer Brown
18 papers
Alan Skarbnik
17 papers
Paul Barr
17 papers
Chaitra Ujjani
16 papers
John Allan
16 papers
Lindsey Roeker
16 papers · 12 as a fellow
Andrea Sitlinger
15 papers · 7 as a fellow
Deborah Stephens
15 papers

Clinical trials

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2038
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 1
Carna Biosciences, Inc.
2023–2027
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Site PI · Recruiting · Phase 1
Catapult Therapeutics
2021–2027